Core Viewpoint - WuXi AppTec reported significant growth in revenue and net profit for the first three quarters of 2025, driven by its focus on the CRDMO business model and operational efficiency improvements [1][3]. Financial Performance - For the first three quarters of 2025, WuXi AppTec achieved operating revenue of RMB 32.857 billion, a year-on-year increase of 18.61% [1]. - The net profit attributable to shareholders reached RMB 12.076 billion, reflecting a substantial year-on-year growth of 84.84% [1][2]. - As of September 30, 2025, the company had a backlog of orders amounting to RMB 59.88 billion, up 41.2% year-on-year [2]. Revenue Breakdown - Revenue from continuous operations for the first three quarters was RMB 32.45 billion, with contributions from various regions: - Revenue from U.S. clients: RMB 22.15 billion, up 31.9% - Revenue from European clients: RMB 3.84 billion, up 13.5% - Revenue from Chinese clients: RMB 5.04 billion, up 0.5% - Revenue from other regions: RMB 1.42 billion, up 9.2% [2]. - The chemical business generated RMB 25.98 billion, a growth of 29.3% [2]. Strategic Moves - WuXi AppTec announced the sale of 100% equity in two subsidiaries for a base price of RMB 2.8 billion to a company under Hillhouse Capital [4]. - The divestiture aligns with the company's strategy to focus on its core CRDMO business, enhancing its global capabilities and operational capacity [4][5]. Future Outlook - The company expects continuous operations revenue growth to return to double digits, with an adjusted growth rate forecast of 17-18% [3]. - Overall revenue guidance for the year has been raised to between RMB 43.5 billion and RMB 44 billion [3].

药明康德表示，本次出售康德弘翼及津石医药100%股权，是公司基于聚焦CRDMO业务模式，专注药物 发现、实验室测试及工艺开发和生产服务考虑所实施，可为公司加速全球化能力和产能的投放提供资金 支持，符合公司发展战略和长远利益。 北京商报讯（记者 丁宁）10月26日晚间，药明康德（603259）发布公告称，公司全资子公司上海药明 康德新药开发有限公司拟以28亿元（为基准股权转让价款，最终股权转让价款将基于交易协议的相关约 定进行调整）的对价向上海世和融企业管理咨询有限公司及上海世和慕企业管理咨询有限公司转让其所 持有的上海康德弘翼医学临床研究有限公司（以下简称"康德弘翼"）和上海药明津石医药科技有限公司 （以下简称"津石医药"）100%股权。 ...

Core Viewpoint - WuXi AppTec (603259) reported a significant increase in revenue and net profit for the first three quarters of 2025, driven by a focus on the CRDMO business model and operational efficiencies [1] Financial Performance - The company achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, marking an impressive year-on-year increase of 84.84% [1] Business Strategy - The growth in performance is attributed to the company's ongoing focus and enhancement of its CRDMO business model, leading to sustained revenue growth [1] - Continuous optimization of production processes and operational efficiency contributed to improved capacity utilization and overall profitability [1] Additional Income Sources - The company also benefited from the sale of part of its stake in the joint venture WuXi XDC Cayman Inc., which further boosted its profits [1]

Core Insights - WuXi AppTec reported Q3 2025 revenue of 12.057 billion yuan, a year-on-year increase of 15.26%, with net profit attributable to shareholders reaching 3.515 billion yuan, up 53.27% [1] - The company’s chemical business remains the main growth driver, with a 29.3% year-on-year revenue increase in the first three quarters [2][5] - The TIDES business (oligonucleotides and peptides) showed exceptional performance, with revenue soaring 121.1% to 7.84 billion yuan [2][5] - The company’s backlog of orders reached 59.88 billion yuan, a significant year-on-year increase of 41.2%, providing a solid foundation for upward adjustments in annual performance guidance [6] Financial Performance - Q3 2025 revenue was 12.057 billion yuan, a 15.26% increase year-on-year; net profit attributable to shareholders was 3.515 billion yuan, up 53.27%; and non-GAAP net profit was 3.940 billion yuan, increasing by 73.75% [1] - For the first three quarters of 2025, total revenue was 32.857 billion yuan, a year-on-year increase of 18.61%; net profit attributable to shareholders was 12.076 billion yuan, up 84.84%; and non-GAAP net profit was 9.522 billion yuan, increasing by 42.51% [1] Business Segment Performance - The chemical business generated 25.98 billion yuan in revenue in the first three quarters, reflecting a 29.3% year-on-year growth [2][5] - The TIDES business achieved revenue of 7.84 billion yuan, marking a remarkable 121.1% increase [2][5] - The small molecule CDMO (D&M) business reported revenue of 14.24 billion yuan, a 14.1% year-on-year growth [3][5] - The testing business showed stagnant performance with revenue of 4.17 billion yuan, nearly unchanged at -0.04% year-on-year, primarily due to a 6.4% decline in clinical CRO and SMO business [3][7] - The biological business experienced a slowdown, with revenue of 1.95 billion yuan, reflecting a 6.6% year-on-year growth [4][7] Market Dynamics - The company continues to rely significantly on overseas markets, with revenue from U.S. clients increasing by 31.9% to 22.15 billion yuan, while revenue from Chinese clients remained flat, growing only 0.5% [7] - The substantial backlog of orders indicates high revenue growth certainty for the upcoming quarters [6]

Core Insights - WuXi AppTec reported a net profit of 3.515 billion yuan for Q3, representing a year-on-year increase of 53.27% [1] - For the first three quarters, the net profit reached 12.076 billion yuan, showing a year-on-year growth of 84.84% [1] - The company continues to focus on and strengthen its CRDMO business model, leading to sustained revenue growth [1] Financial Performance - The net profit for Q3 was 3.515 billion yuan, up 53.27% compared to the same period last year [1] - The net profit for the first three quarters totaled 12.076 billion yuan, reflecting an 84.84% increase year-on-year [1] Business Strategy - The company is optimizing production processes and operational efficiency, contributing to improved overall profitability [1] - Growth in late-stage clinical and commercialization projects has enhanced capacity efficiency [1] - The sale of part of its stake in the joint venture WuXi XDC Cayman Inc. has further boosted the company's profits [1]

Group 1 - The core point of the article is that WuXi AppTec (603259.SH/02359) reported a record high revenue for the third quarter of 2025, with a total revenue of 32.86 billion yuan for the first three quarters, representing a year-on-year growth of 18.6% [1] - The company has raised its full-year revenue target to 43.5-44 billion yuan, indicating strong performance expectations for the remainder of the year [1] - The growth rate of the company's profits has outpaced the revenue growth across various profit metrics, highlighting operational efficiency and profitability improvements [1]

Core Insights - WuXi AppTec (603259.SH, 2359.HK) reported its Q3 financial results on October 26, 2025, showcasing strong growth in revenue and profit [1] Financial Performance - The company achieved a cumulative revenue of 32.86 billion yuan for the first three quarters, representing a year-on-year increase of 18.6% [1] - Adjusted Non-IFRS net profit attributable to the parent company reached 10.54 billion yuan, marking a year-on-year growth of 43.4%, which has already matched the total scale of the previous year [1] - The third quarter alone saw record-high revenue and adjusted net profit, indicating the best quarterly performance in the company's history [1]

Core Viewpoint - WuXi AppTec announced the sale of 100% equity in two subsidiaries for a base price of 2.8 billion yuan, aligning with its strategy to focus on CRDMO business and enhance global capabilities [1] Group 1: Transaction Details - The transaction involves the transfer of equity in Shanghai Kande Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. [1] - The buyers are newly established companies under Hillhouse Capital, which focuses on healthcare, manufacturing, green energy, hard technology, and consumer technology [1] Group 2: Strategic Implications - The sale is part of the company's strategy to concentrate on drug discovery, laboratory testing, and process development and production services [1] - The transaction is expected to provide financial support for accelerating the company's global capabilities and capacity deployment [1]

2025年10月26日，药明康德(603259.SH/2359.HK)发布最新财务数据：前三季度实现营业收入328.6亿 元，同比增长18.6%，三大利润口径上的增速均高于营收水平。药明康德并将全年营收指引上调至435- 440亿元，这是今年内的第二次上调，预计全年持续经营业务收入增速介于17%到18%之间。 ...

Core Insights - WuXi AppTec (603259.SH/2359.HK) reported a strong performance in Q3 2025, achieving a record quarterly revenue exceeding 12 billion yuan [1] - The company's revenue for the first three quarters reached 32.86 billion yuan, reflecting a year-on-year growth of 18.6% [1] - Profit growth across three metrics also showed double-digit increases, indicating robust operational efficiency and financial management [1] - Operating cash flow for the first three quarters was 10.87 billion yuan, marking a significant year-on-year increase of 35% [1]